The most appropriate medication regimen to mitigate the consequences hepatic encephalopathy remains inconclusive. This review seeks to serve as a reference for clinicians to help guide therapy decisions with regard to hepatic encephalopathy.
Methods:
A comprehensive literature review between August 2018 and April 2019 was accomplished with the assistance of a medical librarian. Sources of literature review include PubMed, MEDLINE, SCOPUS, ProQuest Central, CINAHL, and ProQuest Dissertations. The authors selected randomized clinical and double-blind cross-over trials evaluating probiotics, zinc, polyethylene glycol, rifaximin, and flumazenil. Sixteen clinical trials are discussed in this review. Pertinent safety, efficacy, and statistical and clinical outcomes are summarized by the authors.
Conclusions:
The most appropriate regimen to mitigate the consequences of hepatic encephalopathy remains elusive; however, the agents discussed within this review offer alternative options for patients unresponsive to or intolerant of traditional lactulose therapy. This review seeks to serve as a repository for relevant clinical trials, and as a reference for clinicians to help guide therapy decisions.
DharelNBajajJS. Definition and nomenclature of hepatic encephalopathy. J Clin Exp Hepatol. 2015;5(suppl 1):S37–S41. doi:10.1016/j.jceh.2014.10.001
2.
ClayASHainlineBE. Hyperammonemia in the ICU. Chest. 2007;132(4):1368–1378. doi:10.1378/chest.06-2940
3.
VaqueroJChungCCahillME, et al.Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003;23(3):259–269. doi:10.1055/s-2003-42644
4.
CollinsCMD’orazioSE. Bacterial ureases: structure, regulation of expression and role in pathogenesis. Mol Microbiol. 1993;9(5):907–913. doi:10.1111/j.1365-2958.1993.tb01220.x
5.
Romero-gómezMJoverMGalánJJRuizA. Gut ammonia production and its modulation. Metab Brain Dis. 2009;24(1):147–157. doi:10.1007/s11011-008-9124-3
6.
AlbrechtJNorenbergMD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44(4):788–794. doi:10.1002/hep.21357
7.
ButterworthRF. Effects of hyperammonemia on brain function. J Inherit Metab Dis. 1998;21:6–20.
8.
ShawcrossDJalanR. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. 2005;60(20):2295–2304. doi:10.1007/s00018-005-5089-0
9.
McdanielJDavuluriGHillEA, et al.Hyperammonemia results in reduced muscle function independent of muscle mass. Am J Physiol Gastrointest Liver Physiol. 2016;310(3):163–170. doi:10.1152/ajpgi.00322.2015
10.
MouriSTriponSRudlerM, et al.FOUR score, a reliable score for assessing overt hepatic encephalopathy in cirrhotic patients. Neurocrit Care. 2015;22(2):251–257. doi:10.1007/s12028-014-0078-5
11.
VilstrupHAmodioPBajajJ, et al.Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735. doi:10.1002/hep.27210
12.
TranahTHPaolinoAShawcrossDL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liv Dis. 2015;5(3):59–63. doi:10.1002/cld.445
13.
De las herasJAldámiz-echevarríaLMartínez-chantarMLTeresaCD. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease. Expert Opin Drug Metab Toxicol. 2017;13(4):439–448. doi:10.1080/17425255.2017.1262834
14.
CordobaJ.Hepatic encephalopathy: from the pathogenesis to the new treatments. ISRN Hepatol. 2014;2014:236268. doi:10.1155/2014/236268
15.
NabiEBajajJS. Useful tests for hepatic encephalopathy in clinical practice. Curr Gastroenterol Rep. 2014;16(1):362. doi:10.1007/s11894-013-0362-0
16.
RaiRSaraswatVADhimanRK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol. 2015;5(suppl 1):S29–S36. doi:10.1016/j.jceh.2014.12.003
17.
ChenYYangFLuH, et al.Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562–572. doi:10.1002/hep.24423
18.
BajajJSRidlonJMHylemonPB, et al.Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastro Int Liver Physiol. 2012;302(1):168–175. doi:10.1152/ajpgi.00190.2011
19.
BajajJSHeumanDMHylemonPB, et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940–947. doi:10.1016/j.jhep.2013.12.019
20.
ReadAEMcCarthyCFHeatonKWLaidlawJ. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. Brit Med J. 1966;1(5489):1267–1269. doi:10.1136.bmj.1.5498.1267
21.
DawsonAMMcLarenJSherlockS. Neomycin in the treatment of hepatic coma. Lancet. 1957;2(7008):1263. doi:10.1016/s0140-6736(57)91544-1
22.
DhimanRKChawlaYK. Minimal hepatic encephalopathy. Ind J Gastroenterol. 2009;28(1):5–16. doi:10.1007/s12664-009-0003-6
23.
PohZChangPE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:1–10. doi:10.1155/2012/480309
24.
RahmanASandhuAAl-JudaibiBKarimQJeremyBGregorR. Efficacy of probiotic therapy in preventing overt hepatic encephalopathy. Can J Nut. 2016;2016(1):12–18. doi:10.22433/2-16/09/4
25.
BajajJSHeumanDMHylemonPB, et al.Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharm Ther. 2014;39(10):1113–1125. doi:10.1111/apt.12695
26.
LuniaMKSharmaBCSharmaP, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol. 2014;12(6):1003–1008.e1. doi:10.1016/j.cgh.2013.11.006
27.
Ciećko-michalskaISzczepanekMSłowikATomaszM. Pathogenesis of hepatic encephalopathy. Gastroenterol Res Pract. 2012;2012:642108. doi:10.1155/2012/652108
28.
Chavez-tapiaNCCesar-arceABarrientos-gutiérrezTVillegas-LópezFAMéndez-SanchezNMisaelU. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74–80. doi:10.1186/1475-2891-12-74
29.
SchliessFGörgBHäussingerD. RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia. Metab Brain Dis. 2009;24(1):119–134. doi:10.1007/s11011-008-9125-2
AdroverRBarrioMMalca albuquerqueM, et al.Validation of the number connection test for identifying patients with minimal hepatic encephalopathy. Acta Gastroenterol Latinoam. 2012;42(2):105–111.
33.
RedingPDuchateauJBatailleC.Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet. 1984;2(8401):493–495. doi:10.1016/s0140-6736(68)92567-4
34.
BresciGParisiGBantiS. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993;2(7):414–416.
35.
MousaNAbdel-razikAZaherA, et al.The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. Thera Adv Gastroenterol. 2016;9(5):684–691. doi:10.1177-1756283X16645049
36.
SaperRBRashRR. Zinc: an essential micronutrient. Am Fam Physician. 2009;79(9):768–772.
37.
ManningRTDelpM. Management of hepatocerebral intoxication. N Engl J Med. 1958;258(2):55–62. doi:10.1056/NEJM195801092580201
38.
WeberFLFresardKM. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Dig Dis. 1996;14(suppl 1):53–63. doi:10.1159/000171583
39.
BircherJMüllerJGuggenheimPHaemmerliUP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet. 1966;1(7443):890–892. doi:10.1016/s0140-6736(66)91537-x
40.
RahimiRSSingalAGCuthbertJADonCR. Lactulose vs polyethylene glycol 3350—electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727–1733. doi:10.1001/jamainternmed.2014.4746
41.
NaderianMAkbariHSaeediMAli SohrabpourA. Polyethylene glycol and lactulose versus lactulose alone in the treatment of hepatic encephalopathy in patients with cirrhosis: a non-inferiority randomized controlled trial. Middle East J Dig Dis. 2017;9(1):12–19. doi:10.15171.mejdd.2016.46
42.
ShehataHHElfertAAAbdinAA, et al.Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2018;30(12):1476–1481. doi:10.1097/MEG.0000000000001267
43.
HassaneinTBleiATPerryW, et al.Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol. 2009;104(6):1392–1400. doi:10.1038/ajg.2009.160
44.
HuangEEsrailianESpiegelBM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy—a decision analysis. Aliment Pharmacol Ther. 2007;26(8):1147–1161. doi:10.1111/j.1635-2036.2007.03464.x
45.
GerardLGareyKWDupontHL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in non systemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201–211.
46.
BucciLPalmieriGC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13(2):109–118. doi:10.1185.030079993309111539
47.
SamaCMorselli-labateAMPiantaPLauraLSoniaBGabriellaM. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label, pilot study. Curr Ther Res Clin Exp. 2004;65(5):413–422. doi:10.1016/j.curtheres.2004.10.002
48.
MasARodésJSunyerL, et al.Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51–58. doi:10.1016/S0168-8278(02)00350-1
49.
SharmaBCSharmaPLuniaMKSrivastavaSGoyalRSarinSK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–1463. doi:10.1038/ajg.2013.219
50.
NeffGWKemmerNZachariasVC, et al.Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38(10):3552–3555. doi:10.1016/j.transproceed.2006.10.107
51.
LeevyCBPhillipsJA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737–741. doi:10.1007/s10620-006-9442-4
52.
HoffmanEJWarrenEW. Flumazenil: a benzodiazepine antagonist. Clin Pharm. 1993;12(9):641–656.
53.
LaccettiMManesGUomoGLionielloMRabittiPGBalzanoA. Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Digest Liver Dis. 2000;32(4):335–338. doi:10.1016/S1590-8658(00)80027-4
54.
BaraldiMZeneroliML. Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid. Science. 1982;216(4544):427–429. doi:10.1126/science.6280279
55.
CadranelJFEl younsiMPidouxB, et al.Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol. 1995;7(4):325–329.
56.
Van der rijtCCSchalmSWMeulsteeJStijnenT. Flumazenil therapy for hepatic encephalopathy. a double-blind cross over study. Gastroenterol Clin Biol. 1995;19(6-7):572–580.
57.
GroenewegMGyrKAmreinR, et al.Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr Clin Neurophysiol.1996;98(1):29–34. doi:10.1016/0013-4694(95)00200-6
58.
GyrKMeierRHäusslerJ, et al.Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut. 1996;39(2):319–324. doi:10.1136/gut.39.2.319
59.
BarbaroGDi lorenzoGSoldiniM, et al.Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology. 1998;28(2):374–378. doi:10.1002/hep.510280212
60.
DursunMCaliskanMCanorucF, et al.The efficacy of flumazenil in subclinical to mild hepatic encephalopathic ambulatory patients. A prospective, randomised, double-blind, placebo-controlled study. Swiss Med Wkly.2003;133(7-8):118–123.
